Anebulo Pharmaceuticals (ANEB) Competitors $1.21 +0.03 (+2.54%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANEB vs. GNFT, INMB, ESPR, INBX, ACTU, DERM, IPHA, HURA, TVGN, and ACIUShould you be buying Anebulo Pharmaceuticals stock or one of its competitors? The main competitors of Anebulo Pharmaceuticals include Genfit (GNFT), INmune Bio (INMB), Esperion Therapeutics (ESPR), Inhibrx (INBX), Actuate Therapeutics (ACTU), Journey Medical (DERM), Innate Pharma (IPHA), TuHURA Biosciences (HURA), Tevogen Bio (TVGN), and AC Immune (ACIU). These companies are all part of the "pharmaceutical products" industry. Anebulo Pharmaceuticals vs. Genfit INmune Bio Esperion Therapeutics Inhibrx Actuate Therapeutics Journey Medical Innate Pharma TuHURA Biosciences Tevogen Bio AC Immune Genfit (NASDAQ:GNFT) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, profitability, institutional ownership, valuation, risk, dividends and media sentiment. Do analysts rate GNFT or ANEB? Genfit presently has a consensus target price of $13.00, suggesting a potential upside of 217.07%. Anebulo Pharmaceuticals has a consensus target price of $8.00, suggesting a potential upside of 561.16%. Given Anebulo Pharmaceuticals' higher possible upside, analysts plainly believe Anebulo Pharmaceuticals is more favorable than Genfit.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genfit 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Anebulo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings and valuation, GNFT or ANEB? Anebulo Pharmaceuticals has lower revenue, but higher earnings than Genfit. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenfit$76.06M2.70-$31.27MN/AN/AAnebulo PharmaceuticalsN/AN/A-$8.20M-$0.28-4.32 Do insiders & institutionals have more ownership in GNFT or ANEB? 2.2% of Genfit shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 4.2% of Genfit shares are owned by company insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor GNFT or ANEB? In the previous week, Genfit had 2 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 6 mentions for Genfit and 4 mentions for Anebulo Pharmaceuticals. Anebulo Pharmaceuticals' average media sentiment score of 0.31 beat Genfit's score of 0.14 indicating that Anebulo Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genfit 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anebulo Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, GNFT or ANEB? Genfit has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, Anebulo Pharmaceuticals has a beta of -1.13, indicating that its stock price is 213% less volatile than the S&P 500. Is GNFT or ANEB more profitable? Genfit's return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets GenfitN/A N/A N/A Anebulo Pharmaceuticals N/A -119.54%-108.08% Does the MarketBeat Community believe in GNFT or ANEB? Genfit received 60 more outperform votes than Anebulo Pharmaceuticals when rated by MarketBeat users. However, 90.00% of users gave Anebulo Pharmaceuticals an outperform vote while only 69.70% of users gave Genfit an outperform vote. CompanyUnderperformOutperformGenfitOutperform Votes6969.70% Underperform Votes3030.30% Anebulo PharmaceuticalsOutperform Votes990.00% Underperform Votes110.00% SummaryGenfit and Anebulo Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks. Get Anebulo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANEB vs. The Competition Export to ExcelMetricAnebulo PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.48M$6.89B$5.56B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-4.327.4422.4818.48Price / SalesN/A242.70395.10103.59Price / CashN/A65.8538.1834.62Price / Book8.076.516.774.25Net Income-$8.20M$143.21M$3.22B$248.23M7 Day Performance12.04%1.98%1.50%0.89%1 Month Performance1.68%6.89%4.01%3.53%1 Year Performance-59.12%-2.52%16.16%5.08% Anebulo Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANEBAnebulo Pharmaceuticals2.0105 of 5 stars$1.21+2.5%$8.00+561.2%-58.3%$48.48MN/A-4.324Short Interest ↑News CoverageGNFTGenfit1.3588 of 5 stars$3.67+0.8%$13.00+254.2%+17.1%$183.49M$76.06M0.00120Short Interest ↑Gap UpINMBINmune Bio2.3963 of 5 stars$7.90+1.0%$22.80+188.6%-33.6%$181.57M$14,000.00-3.6210Upcoming EarningsNews CoveragePositive NewsESPREsperion Therapeutics3.4168 of 5 stars$0.91-1.4%$6.42+607.2%-49.3%$179.78M$332.31M-1.42200Upcoming EarningsAnalyst RevisionNews CoverageINBXInhibrx2.552 of 5 stars$12.35+0.7%N/A-63.8%$178.78M$200,000.000.00166Short Interest ↓Positive NewsACTUActuate TherapeuticsN/A$9.05+1.1%$20.50+126.5%N/A$176.77MN/A0.0010DERMJourney Medical2.6804 of 5 stars$7.58+1.5%$9.88+30.3%+101.1%$175.13M$56.13M-8.0690Short Interest ↑News CoverageIPHAInnate Pharma2.5683 of 5 stars$2.09+5.5%$11.00+426.6%-3.5%$175.12M$12.63M0.00220Analyst RevisionGap UpHURATuHURA BiosciencesN/A$3.97-3.2%$12.67+219.1%N/A$173.41MN/A0.00N/APositive NewsTVGNTevogen Bio3.0949 of 5 stars$0.94-5.5%$7.10+657.4%+3.0%$172.38MN/A0.003Analyst ForecastACIUAC Immune2.5414 of 5 stars$1.70+3.7%$12.00+605.9%-30.2%$170.70M$27.31M-3.70140News CoveragePositive News Related Companies and Tools Related Companies Genfit Alternatives INmune Bio Alternatives Esperion Therapeutics Alternatives Inhibrx Alternatives Actuate Therapeutics Alternatives Journey Medical Alternatives Innate Pharma Alternatives TuHURA Biosciences Alternatives Tevogen Bio Alternatives AC Immune Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANEB) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anebulo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anebulo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ANEB Stock Free ANEB Stock Alerts